Award
NIH Reporter #11384975
Investigating immunomodulation of p53 mutant ovarian cancer
Recipient
Thomas Jefferson University
Award Amount
$51,477.00
Ceiling
$51,477.00
Awarded
August 06, 2026
Identifier
11384975
This NIH-funded project at Thomas Jefferson University investigates how MDM2 degradation affects immune signaling in p53 mutant ovarian cancer, aiming to improve anti-tumor immunity and develop new treatments.
Description
The project focuses on the molecular mechanisms by which MDM2 degradation triggers immune signaling pathways in high grade serous ovarian cancer (HGSOC). It aims to investigate effects on the tumor microenvironment and enhance anti-tumor immunity. The project involves developing and testing a PROTAC to target MDM2 for degradation, with potential translational applications in ovarian cancer treatment. The study will interface with clinicians and scientists to foster training in translational cancer research.